We are proud that the MTHFD2 inhibitors are now published in the prestigious journal Nature Cancer. In this first report, we describe that MTHFD2 inhibitors deplete cells of thymidine, specifically in cancer cells. We show that the loss of thymidine causes replication stress, which is a hallmark for DNA damage response (DDR) inhibitors and placing our MTHFD2 inhibitors in the DDR space. Finally, we show acute myeloid leukemia (AML) being targeted by the treatment and provides new hope for this cancer type.
One-carbon therapeutics AB management at ESMO to discuss the ODIN clinical phase 1/2 trial with potential clinical sites across Europe
One-carbon therapeutics AB is discussing the ODIN trial with several
